

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant To Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (date of earliest event reported): December 28, 2005

ANGIODYNAMICS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

0-50761

(Commission File Number)

11-3146460

(IRS Employer Identification No.)

603 Queensbury Avenue, Queensbury, New York

(Address of Principal Executive Offices)

12804

(Zip Code)

(518) 798-1215

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions.

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

(b) On December 28, 2005, AngioDynamics, Inc. (the "Company") learned of the death that same day of Howard S. Stern, a director and co-founder of the Company. On January 3, 2006, the Company issued a press release announcing Mr. Stern's death. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference in its entirety.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

[99.1 Press Release issued by AngioDynamics, Inc. on January 3, 2006.](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 4, 2006

ANGIODYNAMICS, INC.
(Registrant)

By: /s/ Joseph G. Gerardi
Joseph G. Gerardi
Vice President, Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit</u>	<u>Description</u>
99.1	Press Release issued by AngioDynamics, Inc. on January 3, 2006.



Company Contacts:

AngioDynamics, Inc.
Jennifer Chase
518-798-1215 ext. 370
www.angiodynamics.com

Investor Relations Contacts:

Lippert/Heilshorn & Associates, Inc.
Kim Sutton Golodetz (kgolodetz@lhai.com)
(212) 838-3777
Bruce Voss (bvoss@lhai.com)
(310) 691-7100

ANGIODYNAMICS MOURNS LOSS OF CO-FOUNDER, DIRECTOR HOWARD S. STERN

QUEENSBURY, N.Y. (January 3, 2006) – AngioDynamics, Inc. (Nasdaq: ANGO) regrets to announce that Howard S. Stern, its co-founder, former chairman of the board of directors, and current director has passed away at the age of 74 after losing his battle with brain cancer.

Mr. Stern co-founded AngioDynamics in 1988 as a division of E-Z-EM, Inc., (Nasdaq:EZEM). He served as a director of the Company since its inception until his death, and was chairman of the board of directors from the Company's inception until February 2004.

Eamonn P. Hobbs, president and chief executive officer of AngioDynamics commented, "We have lost a remarkable man. Howard's insight into the possibilities for the treatment of peripheral vascular disease has made a difference in the lives of patients, and in the physicians who treat them. He was instrumental in guiding AngioDynamics from a development stage company to its present position as a publicly-traded leader in innovative products for the PVD marketplace. We will miss Howard dearly and extend our deepest sympathies to his family."

About AngioDynamics

AngioDynamics, Inc. (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, vascular surgeons and other physicians for the minimally invasive diagnosis and treatment of peripheral vascular disease. AngioDynamics designs, develops, manufactures and markets a broad line of therapeutic and diagnostic devices that enable interventional physicians, such as interventional radiologists, vascular surgeons and others, to treat peripheral vascular diseases and other non-coronary diseases. The Company's diverse product line includes angiographic catheters, hemodialysis catheters, endovascular laser venous system products, PTA dilation balloon catheters, image-guided vascular access products, thrombolytic products and drainage products.

###